NASDAQ:RPRX - Repros Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.67 -0.01 (-1.47 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$0.6765
Today's Range$0.6650 - $0.6750
52-Week Range$0.26 - $1.33
Volume251,774 shs
Average Volume473,590 shs
Market Capitalization$26.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.45
Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Receive RPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:RPRX
CUSIP76028H20
Phone+1-281-7193400

Debt

Debt-to-Equity RatioN/A
Current Ratio1.18
Quick Ratio1.18

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00
Price / Sales530.10
Cash FlowN/A
Price / CashN/A
Book Value$0.24 per share
Price / Book2.79

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-17,270,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-134.23%

Miscellaneous

Employees24
Outstanding Shares39,560,000
Market Cap$26.50

The Truth About Cryptocurrencies

Repros Therapeutics (NASDAQ:RPRX) Frequently Asked Questions

What is Repros Therapeutics' stock symbol?

Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."

How were Repros Therapeutics' earnings last quarter?

Repros Therapeutics Inc (NASDAQ:RPRX) posted its quarterly earnings data on Monday, November, 13th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.24. The biotechnology company had revenue of $0.30 million for the quarter. View Repros Therapeutics' Earnings History.

What price target have analysts set for RPRX?

1 brokers have issued 1 year price targets for Repros Therapeutics' stock. Their predictions range from $0.39 to $0.39. On average, they anticipate Repros Therapeutics' share price to reach $0.39 in the next twelve months. This suggests that the stock has a possible downside of 41.8%. View Analyst Ratings for Repros Therapeutics.

What is the consensus analysts' recommendation for Repros Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repros Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are Repros Therapeutics' key executives?

Repros Therapeutics' management team includes the folowing people:
  • Patrick P. Fourteau, Chairman of the Board (Age 69)
  • Larry M Dillaha M.D., President, Chief Executive Officer, Director (Age 53)
  • Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary (Age 58)
  • Joachim F. Wernicke, Chief Medical Officer (Age 68)
  • Daniel F. Cain, Independent Director (Age 70)
  • Nola E. Masterson, Independent Director (Age 69)
  • Saira Ramasastry, Independent Director (Age 40)
  • Michael G. Wyllie Ph.D., Independent Director (Age 65)

Has Repros Therapeutics been receiving favorable news coverage?

News articles about RPRX stock have trended somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repros Therapeutics earned a news impact score of 0.05 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.47 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Repros Therapeutics?

Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repros Therapeutics' stock price today?

One share of RPRX stock can currently be purchased for approximately $0.67.

How big of a company is Repros Therapeutics?

Repros Therapeutics has a market capitalization of $26.50 million and generates $50,000.00 in revenue each year. Repros Therapeutics employs 24 workers across the globe.

How can I contact Repros Therapeutics?

Repros Therapeutics' mailing address is 2408 Timberloch Pl Ste B7, THE WOODLANDS, TX 77380-1021, United States. The biotechnology company can be reached via phone at +1-281-7193400 or via email at [email protected]


MarketBeat Community Rating for Repros Therapeutics (NASDAQ RPRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe RPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.